A framework for the estimation of treatment costs of cardiovascular conditions in the presence of disease transition

Show simple item record

dc.contributor.author Goswami, Mohit
dc.contributor.author Daultani, Yash
dc.contributor.author Paul, Sanjoy Kumar
dc.contributor.author Pratap, Saurabh
dc.date.accessioned 2023-04-25T11:26:00Z
dc.date.available 2023-04-25T11:26:00Z
dc.date.issued 2022
dc.identifier.issn 02545330
dc.identifier.uri http://localhost:8080/xmlui/handle/123456789/2272
dc.description This paper is submitted by the author of IIT (BHU), Varanasi en_US
dc.description.abstract The current research aims to aid policymakers and healthcare service providers in estimating expected long-term costs of medical treatment, particularly for chronic conditions characterized by disease transition. The study comprised two phases (qualitative and quantitative), in which we developed linear optimization-based mathematical frameworks to ascertain the expected long-term treatment cost per patient considering the integration of various related dimensions such as the progression of the medical condition, the accuracy of medical treatment, treatment decisions at respective severity levels of the medical condition, and randomized/deterministic policies. At the qualitative research stage, we conducted the data collection and validation of various cogent hypotheses acting as inputs to the prescriptive modeling stage. We relied on data collected from 115 different cardio-vascular clinicians to understand the nuances of disease transition and related medical dimensions. The framework developed was implemented in the context of a multi-specialty hospital chain headquartered in the capital city of a state in Eastern India, the results of which have led to some interesting insights. For instance, at the prescriptive modeling stage, though one of our contributions related to the development of a novel medical decision-making framework, we illustrated that the randomized versus deterministic policy seemed more cost-competitive. We also identified that the expected treatment cost was most sensitive to variations in steady-state probability at the “major” as opposed to the “severe” stage of a medical condition, even though the steady-state probability of the “severe” state was less than that of the “major” state. en_US
dc.language.iso en en_US
dc.publisher Springer en_US
dc.relation.ispartofseries Annals of Operations Research;
dc.subject Healthcare systems en_US
dc.subject Markovian analysis en_US
dc.subject Medical decision-making en_US
dc.subject Resource planning en_US
dc.title A framework for the estimation of treatment costs of cardiovascular conditions in the presence of disease transition en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search in IDR


Advanced Search

Browse

My Account